# 1 4 U Pharma GmbH Company profile · SME (from the award notice) - Legal form: GmbH - Seat: Densborn, Germany Based on the notices and sources Inteliwert covers; not a complete record. Last checked 1 October 2024. ## Identifiers - Register entry: HRB 44730 As the covered sources state them. ## Track record in public tenders Awards in the covered notices over the last 36 months, per CPV division. | CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award | | --- | ---: | ---: | ---: | ---: | --- | --- | | 33 Medical equipments, pharmaceuticals and personal care products | 1 | — | 1 | 0 | 1 October 2024 | 1 October 2024 | Based on the notices and sources Inteliwert covers; not a complete record. ### Awards - [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Dapagliflozin, ATC A10BK01 für die Zeit 01.10.2024 - 30.09.2026](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum) Buyer: DAK-Gesundheit · Awarded: 1 October 2024 · CPV 33600000 ## Certifications and prequalification No certification or prequalification found in the covered sources. A certification missing here is unknown, not absent. ## Website and LinkedIn Not found in the indexed notices. ## Open tenders that might fit *Possible match based on public information* Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances. - [Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.11.2026](https://inteliwert.com/tender/opp_ZNQGGTSF8DG34J2QFXDAFH2JYX/abschluss-nicht-exklusiver-rabattvereinbarungen-nach-130-a-abs-8-sgb-v-ab-dem-01) Open · SME (from the award notice) · New to public tenders · Buyer: GWQ ServicePlus AG · Deadline: 10 May 2028, 10:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/0e2746c7-db16-47a3-b77d-17ce06316d19), Last checked 6 Nov 2026, 22:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 6 Nov 2026 - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 6 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 6 Nov 2026 - [Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.12.2026](https://inteliwert.com/tender/opp_9GHGE5H6C45WEMJ9GC4SYZ44PE/abschluss-nicht-exklusiver-rabattvereinbarungen-nach-130-a-abs-8-sgb-v-ab-dem-01) Open · SME (from the award notice) · New to public tenders · Buyer: GWQ ServicePlus AG · Deadline: 10 May 2028, 10:00 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/7dd0ffce-206a-4d6d-832d-9b3e29900533), Last checked 4 Nov 2026, 14:10 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same country as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Clobetasol, ATC D07AD01](https://inteliwert.com/tender/opp_0X4X8DE7RGP1V7F63TVJVH8KTZ/open-house-arzneimittelrabattvertraege-zum-wirkstoff-clobetasol-atc-d07ad01) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/2e2081b0-6e1b-41e6-bdfe-5065bd9741e9), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Ebastin, ATC R06AX22](https://inteliwert.com/tender/opp_E55KBX4QXBSJETFFBC5GBJYWAQ/open-house-arzneimittelrabattvertraege-zum-wirkstoff-ebastin-atc-r06ax22) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/277ab6ab-75a0-4386-b310-fcea5a5ffe88), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Edoxaban, ATC B01AF03](https://inteliwert.com/tender/opp_51MT44C6EZZ844DG8XHE85APP8/open-house-arzneimittelrabattvertraege-zum-wirkstoff-edoxaban-atc-b01af03) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/0d0078d7-fe06-4755-b23d-5c629375c951), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Golimumab, ATC L04AB06](https://inteliwert.com/tender/opp_CEHRPTRSYKK4J68HEDXTRVRYHK/open-house-arzneimittelrabattvertraege-zum-wirkstoff-golimumab-atc-l04ab06) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/fc4864b1-b6a0-4beb-af84-10afd76f7dc7), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Betamethason, ATC D07XC01](https://inteliwert.com/tender/opp_8V2VBWAT1WZ224A4YAQVKS0HGF/open-house-arzneimittelrabattvertraege-zum-wirkstoff-betamethason-atc-d07xc01) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/2f4fcfe1-99b7-4403-92ec-c56bcbe95ec7), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Ponesimod, ATC L04AE04](https://inteliwert.com/tender/opp_7F9E2KW91N5XT9M33CWDBNW494/open-house-arzneimittelrabattvertraege-zum-wirkstoff-ponesimod-atc-l04ae04) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/797d1407-9fda-476b-a332-baf113d609ae), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Erythropoietin, ATC B03XA01](https://inteliwert.com/tender/opp_STEYKQCQ5CRM8REN6PZPP18E9A/open-house-arzneimittelrabattvertraege-zum-wirkstoff-erythropoietin-atc-b03xa01) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/2e5c9586-5242-40a3-bbf3-3679ec2931b6), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - [Open house Arzneimittelrabattverträge zum Wirkstoff Sultiam, nur Filmtabletten, ATC N03AX03](https://inteliwert.com/tender/opp_HVSK2AP5TWY9J4N11C2V8QMM76/open-house-arzneimittelrabattvertraege-zum-wirkstoff-sultiam-nur-filmtabletten-a) Open · SME (from the award notice) · New to public tenders · Buyer: AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse · Deadline: 31 Aug 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/d5f0a744-8115-4766-a7b6-e91abb78f02c), Last checked 7 Nov 2026, 10:30 (UTC+01:00) - Won a contract in CPV group 336 (2024-10-01): [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 - Seat in the same federal state as the place of performance: [Evidence](https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51), checked 7 Nov 2026 - 1 award in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_PVM8MRN4TB7T2AG6K9H1JH3Q56/abschluss-einer-nicht-exklusiven-rabattvereinbarung-nach-130a-absatz-8-sgb-v-zum), checked 7 Nov 2026 ## Is this your company? Send corrections, or ask us to remove the profile, to . You can also ask that the company never be tagged on LinkedIn. ## About this profile Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances. **Based on the notices and sources Inteliwert covers; not a complete record.** Last checked 1 October 2024. --- Page: https://inteliwert.com/company/org_77R382Q0XN4H75VVKXZP7ZGG51/1-4-u-pharma-gmbh Inteliwert is a product of Bandpey GmbH, an international data and AI software company in Munich, Germany, founded and led by Roozbeh Bandpey. Bandpey's products: Facthory, Emolysis, Copolly and Inteliwert. Inteliwert on LinkedIn: https://www.linkedin.com/company/intelliwert, GitHub: https://github.com/inteliwertai.